非消耗性抗CD19抗体会损害B细胞功能,并抑制自身免疫性疾病
Jeffrey S Boyles1, Dorota Sadowski2, Scott Potter2
1Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
一个新的抗CD19抗体,LY3541860,显示强大的B细胞抑制没有耗尽. 与当前的治疗方法相比,这种疗法可能在自身免疫性疾病中提供更好的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在自身免疫性疾病中,B细胞起着关键作用.
- 目前的B细胞枯竭疗法是有效的,但有局限性.
- 需要新的,非消耗性B细胞疗法.
研究的目的:
- 为了评估一种新型,非消耗性抗人类CD19抗体的疗效,LY3541860.
- 在自身免疫模型中,将LY3541860与现有的B细胞向疗法进行比较.
主要方法:
- 在实验室中使用原始人类B细胞进行研究.
- 使用人性化小鼠进行体内研究.
- 在多个B细胞依赖的自身免疫疾病模型中的评估.
主要成果:
- LY3541860强烈抑制人类B细胞的激活,增殖和分化.
- LY3541860在人性化小鼠中显示出有效性.
- 抗小鼠CD19抗体在自身免疫模型中显示出对CD20枯竭的疗效有所改善.
结论:
- LY3541860是一种强大的B细胞抑制剂,具有非耗尽机制.
- 抗CD19治疗可能在没有B细胞枯竭的情况下为自身免疫疾病提供更高的疗效.
更多相关视频
09:41Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
Published on: January 20, 2023
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
相关概念视频
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
